Biomerica Closes $8 Million Public Offering

Stradling client Biomerica, Inc. announced the closing of a confidentially-marked underwritten public offering of common stock, resulting in gross proceeds of $8 million. Craig-Hallum acted as the sole managing underwriter of the offering.

Biomerica is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point of care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases.